Forward-Looking Statement

This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive,” and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in Nemaura’s filings with the Securities and Exchange Commission (the “Commission”), including the risks identified under the section captioned “Risk Factors” in Nemaura’s Quarterly Report on Form 10-Q filed with the Commission on February 09, 2018 and in Nemaura’s Registration Statement on Form S-3 filed with the Commission on March 18, 2016. Nemaura disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Continuous Glucose Monitoring (CGM) TAM

An $82Bn global opportunity

- Global Total Addressable Market for CGM worth $82Bn per annum:
  - Type I Insulin Users: $31.4B
  - Type II Insulin Users: $38.0B
  - Type II Non-Insulin Users: $12.6B

- Type II Insulin & Non-Insulin users are core sugarBEAT® markets with TAM of $69.4B

- Above excludes pre-diabetics population, which is circa 3 times as large
Continuous Glucose Monitoring (CGM)\(^1\)

CGM is currently not widely adopted but adoption is growing fast

- U.S. has largest number of CGM users globally
- Only 2.6% of US diabetics use CGM in 2018 (estimated 630k users out of total 24.6M diagnosed diabetics)
- US annual CGM usage increased by 117% (estimated 630k users in 2018 v 290k users in 2017)
- 30% of US type I diabetics (~5% of all diabetics) use CGM
- 3% of US type II insulin users (~15% of all diabetics) use CGM
- CGM usage amongst non-insulin users and pre-diabetics negligible

\(^1\)PiperJaffray Company Note DXCM Sep 5 2018
Moving Beyond Finger Stick and A1c

Why is CGM better than finger stick readings and A1C for managing glucose?

- CGM transforms ability to better manage glucose levels by providing real-time constant stream of glucose readings, typically at 5 min intervals.

- CGM therefore enables a new metric to be developed for managing glucose beyond finger stick and A1c.

- This new metric is measuring how much time per day glucose levels are kept within normal range.

- CGM currently predominantly used to guide insulin dosage decisions. 80% of diabetics do not use insulin but still need to manage glucose.
Core Proposition

Expanding Continuous Glucose Monitoring (CGM) to:

(i) all people with diabetes

(Total Addressable Market $82Bn$)

(ii) and all pre-diabetics

(nearly 3x as many people as diabetic market)
Current CGM Options Lack What Diabetes Patients Want

How does our CGM differ?

SugarBEAT® can be worn on non-consecutive days given 24 hour patch wear time

SugarBEAT® Differentiates itself from others by Focusing on a Non-Invasive, Cost-Effective, and Flexible solution
What’s Different then?

- Market Leaders use invasive devices, and a large needle to puncture the skin to insert the sensor.
- Our Device is a World first non-invasive system – sits on top of the skin.
What are the benefits of non-invasive?

- No need to wear the device permanently for up to 14 days
- Wear device for the hours and days you choose
- Lower cost, combined with flexible wear means lower overall cost – Affordable
**Anticipated Pricing**

SugarBEAT® may cost **less than one third / one fifth the cost of competitor products** if worn on **alternate day / twice weekly** basis.

<table>
<thead>
<tr>
<th>Sector</th>
<th>Number of Patches / Month</th>
<th>Cost</th>
</tr>
</thead>
</table>
| Insulin users     | • 16 Patches  
                    • Annual Subscription  
                    • Inclusive of transmitter and recharger                   | $35 per month |
| Non-insulin users | • 8 Patches  
                    • Annual Subscription  
                    • Inclusive of transmitter and recharger                   | $20 per month |

*To be confirmed*
SugarBEAT® consists of three components:

1. Daily-disposable adhesive skin-patch (up to 24 hour wear time with 30-60 minute warm up)
2. A rechargeable transmitter (integrated into skin-patch)
3. An app displaying glucose readings (at regular five minute intervals)

SugarBEAT® intended for adjunctive use
Milestones Achieved for NMRD, but the Future is Even Brighter

1Q 2016: SugarBEAT® receives CE Mark in Europe on Predecessor Product (wristwatch)

4Q 2017: Successful 525 patient trial Completed in Europe for SugarBEAT®

1Q 2018: NMRD IPO on Nasdaq

3Q 2018: Published interim FDA clinical data

4Q 2018: Complete FDA Clinical Trials

1Q 2019: Submit FDA approval

Q1 2020: FDA approval for SugarBEAT®

4Q 2018: CE Mark Approval & UK Commercial Launch

2Q 2019: Commercial launch expected in Europe

Significant Future Catalysts in Timeline of NMRD Make for a Compelling Investment Case
FDA Submission – De-Novo 510(k) Route

- De-Novo 510(k) denotes lower risk (Class II graded medium risk)

- Quicker review process compared with PMA which is Class III graded (higher risk)

- The recent De-Novo and subsequent 510(k) by Dexcom provide evidence that current FDA thinking on invasive CGM devices for therapeutic use are suitable for classification as Class II.

- SugarBEAT® is non-invasive and adjunctive, and therefore lower risk.
Interim Comparative MARD for FDA In-Clinic phase as Primary Accuracy Metric

<table>
<thead>
<tr>
<th>Device</th>
<th>Calibration Type</th>
<th>Overall MARD (20%/20mg/dL)</th>
<th>% Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexcom G5*</td>
<td>no. of calibrations not known</td>
<td>9.00</td>
<td>94.00</td>
</tr>
<tr>
<td>sugarBEAT</td>
<td>1-point calibration</td>
<td>8.77</td>
<td>62.61</td>
</tr>
<tr>
<td></td>
<td>2-point calibration</td>
<td>7.97</td>
<td>74.00</td>
</tr>
<tr>
<td></td>
<td>1-point calibration</td>
<td>12.19</td>
<td>79.91</td>
</tr>
<tr>
<td></td>
<td>2-point calibration</td>
<td>10.65</td>
<td>88.57</td>
</tr>
</tbody>
</table>

Full dataset available to view at [http://nemauramedical.com/publications/](http://nemauramedical.com/publications/)

* [https://dexcom.gcs-web.com/static-files/0a1461dd-e75a-4759-9ddf-50b834756bdd](https://dexcom.gcs-web.com/static-files/0a1461dd-e75a-4759-9ddf-50b834756bdd)
Active R&D Pipeline

**Product**

- **SugarBEAT Wellbeing**
  - Key Features:
    - Zero finger stick calibration
    - Synch with wearable tech products
    - Potential for qualitative information
  - Market: Wellness / Wearable Tech

- **SugarBEAT* Gen II**
  - Key Features:
    - Include Pediatric Cover
    - Improved Accuracy (MARD)
    - Longer patch wear time (72 hours)
  - Market: Diabetics + Pre-Diabetics

- Platform technology can be adapted to apply to broad range of analytes beyond glucose

* 18-24 month development timeframe

** 36 month development timeframe
BEAT™ Platform Future R&D Pipeline

**Analyte**

- **Phenylalanine**
  - Phenylalanine monitoring to ensure that the level is sufficiently suppressed
  - **Uses**
  - **Diagnostics**
    - Phenylketonuria (PKU)

- **Prostaglandin**
  - Screening for inflammatory irritants in formulations during drug and cosmetic development
  - **Inflammation**

- **Lactate**
  - Lactate monitoring in intensive care
  - **Anaerobic Metabolism**

- **Various**
  - Monitoring the impact of drug treatment for treatment-regimen calibration and pharmacokinetics
  - **Treatment Regimen Optimization**

- **Lactate (Lifestyle Product)**
  - Lactate monitoring for performance training
  - **Healthcare**

*Projected 30 month development timeframe per analyte*
Management

Dr. Dewan Fazlul Hoque Chowdhury  
Chief Executive Officer

- Over 18 years’ experience in the pharmaceutical and medical device industry and holder of over 50 patents across more than 15 patent families
- 2009-Present: President, Chief Executive Officer and Board Director in charge of research and development of core technologies, product development, innovation and commercialization; coordinates and oversees legal compliance; development of the company mission; policy and planning
- 2005- 2009: founder and CEO of Microneedle Technologies and Nemaura Pharma Limited; developed and launched a microneedle device used in skin clinics; responsible for negotiating licensing deals for a transdermal patch to treat Alzheimer's disease currently under FDA review
- MSc in Microsystem and nanotechnology, from Cranfield University and PhD in Nanomedicine from Oxford University

Iain Anderson  
Chief Financial Officer

- Chartered Certified Accountant since 1992
- Over twenty years' experience with US-owned businesses, including subsidiaries of Hitachi, TriMas Corporation, Precision Castparts Corporation and Hospira Inc.
- Qualified whilst working for the Big Four UK practice of Touche Ross (now Deloitte)
- Joined Nemaura Medical Inc in August 2016
- Gained an MBA from Loughborough University in 1999

Bashir Timol  
Chief Business Officer

- Co-founded, managed and funded several life sciences and medical device companies
- Led investment consortium that provided first two rounds of funding for Nemaura Medical
- 2013-Present: Board Member NMRD
- April 18 – Present: CBO NMRD
- 2007-Present: Investor and NED at Nemaura Pharma Ltd, which offers precise, easy to use and minimally invasive skin based drug delivery technologies
- 2016 -Present: Investor and NED at Diagnostax Limited, which helps accountants provide better tax advice to more of their clients through cloud based software
- Bachelor degree in Economics from the Univ of Central Lancashire, UK.
### Market Data

<table>
<thead>
<tr>
<th>Nemaura Medical Inc.</th>
<th>NASDAQ:NMRD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fiscal Year:</strong></td>
<td>March</td>
</tr>
<tr>
<td><strong>Industry:</strong></td>
<td>Medical Devices</td>
</tr>
<tr>
<td><strong>Recent Share Price (Nov 9 2018)</strong></td>
<td>$1.95</td>
</tr>
<tr>
<td><strong>Market Cap</strong></td>
<td>$400M</td>
</tr>
<tr>
<td><strong>Shares Outstanding:</strong></td>
<td>205.0 million</td>
</tr>
<tr>
<td><strong>Warrants Outstanding:</strong></td>
<td>10.0 million (strike price of $0.50)</td>
</tr>
<tr>
<td><strong>Equity Float:</strong></td>
<td>59.0 million</td>
</tr>
<tr>
<td><strong>Insider Ownership:</strong></td>
<td>71%</td>
</tr>
<tr>
<td><strong>50 Day Average Daily Volume:</strong></td>
<td>152,040</td>
</tr>
<tr>
<td><strong>Balance Sheet (30 Sep 2018)</strong></td>
<td>$3.786M</td>
</tr>
</tbody>
</table>